Revolutionizing Cancer Treatment: Apollomics’ Vebreltinib Shows Remarkable Efficacy in Clinical Trial
Apollomics, a pioneering clinical-stage biopharmaceutical company, unveiled compelling efficacy and safety data for its groundbreaking drug, vebreltinib, derived from the KUNPENG clinical trial, during the
